Taal W - Search Results

1

Are we done with dose-intense temozolomide in recurrent glioblastoma?

van den Bent MJ, Taal W. van den Bent MJ, et al. Among authors: taal w. Neuro Oncol. 2014 Sep;16(9):1161-3. doi: 10.1093/neuonc/nou157. Epub 2014 Jul 25. Neuro Oncol. 2014. PMID: 25063550 Free PMC article. No abstract available.

2

[Favourable result for temozolomide in recurrent high-grade glioma].

Taal W, van der Rijt CD, Sillevis Smitt PA, Kros JM, van Heuvel I, Enting RH, van den Bent MJ. Taal W, et al. Ned Tijdschr Geneeskd. 2005 Jun 18;149(25):1393-9. Ned Tijdschr Geneeskd. 2005. PMID: 15997692 Dutch.

3

[A patient with sinus thrombosis associated with paroxysmal nocturnal hemoglobinuria].

Visser AM, Kappers-Klunne MC, Cornelissen JJ, van den Bent MJ, Taal W. Visser AM, et al. Among authors: taal w. Ned Tijdschr Geneeskd. 2005 Jul 2;149(27):1528-32. Ned Tijdschr Geneeskd. 2005. PMID: 16032999 Dutch.

4

[Clinical reasoning and decision-making in practice. An older man with prostate carcinoma and a painless paraparesis of the legs].

Ruitenberg A, Vecht ChJ, van den Bent MJ, Taal W. Ruitenberg A, et al. Among authors: taal w. Ned Tijdschr Geneeskd. 2005 Aug 6;149(32):1785-90. Ned Tijdschr Geneeskd. 2005. PMID: 16121663 Dutch.

5

Two exceptional phenomena in an anaplastic oligo-astrocytoma.

Hanse MC, Franssen JH, Sleeboom HP, Hoffmann CF, Taal W. Hanse MC, et al. Among authors: taal w. J Neurooncol. 2006 Jun;78(2):197. doi: 10.1007/s11060-005-9088-7. Epub 2006 Mar 31. J Neurooncol. 2006. PMID: 16575535 No abstract available.

6

Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas.

Brandsma D, Stalpers L, Taal W, Sminia P, van den Bent MJ. Brandsma D, et al. Among authors: taal w. Lancet Oncol. 2008 May;9(5):453-61. doi: 10.1016/S1470-2045(08)70125-6. Lancet Oncol. 2008. PMID: 18452856 Review.

7

Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide.

Taal W, Brandsma D, de Bruin HG, Bromberg JE, Swaak-Kragten AT, Smitt PA, van Es CA, van den Bent MJ. Taal W, et al. Cancer. 2008 Jul 15;113(2):405-10. doi: 10.1002/cncr.23562. Cancer. 2008. PMID: 18484594 Free article.

8

IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide.

Dubbink HJ, Taal W, van Marion R, Kros JM, van Heuvel I, Bromberg JE, Zonnenberg BA, Zonnenberg CB, Postma TJ, Gijtenbeek JM, Boogerd W, Groenendijk FH, Smitt PA, Dinjens WN, van den Bent MJ. Dubbink HJ, et al. Among authors: taal w. Neurology. 2009 Nov 24;73(21):1792-5. doi: 10.1212/WNL.0b013e3181c34ace. Neurology. 2009. PMID: 19933982 Clinical Trial.

9

MGMT promoter hypermethylation is a frequent, early, and consistent event in astrocytoma progression, and not correlated with TP53 mutation.

Groenendijk FH, Taal W, Dubbink HJ, Haarloo CR, Kouwenhoven MC, van den Bent MJ, Kros JM, Dinjens WN. Groenendijk FH, et al. Among authors: taal w. J Neurooncol. 2011 Feb;101(3):405-17. doi: 10.1007/s11060-010-0274-x. Epub 2010 Jul 1. J Neurooncol. 2011. PMID: 20593220 Free PMC article.

10

First-line temozolomide chemotherapy in progressive low-grade astrocytomas after radiotherapy: molecular characteristics in relation to response.

Taal W, Dubbink HJ, Zonnenberg CB, Zonnenberg BA, Postma TJ, Gijtenbeek JM, Boogerd W, Groenendijk FH, Kros JM, Kouwenhoven MC, van Marion R, van Heuvel I, van der Holt B, Bromberg JE, Sillevis Smitt PA, Dinjens WN, van den Bent MJ; Dutch Society for Neuro-Oncology. Taal W, et al. Neuro Oncol. 2011 Feb;13(2):235-41. doi: 10.1093/neuonc/noq177. Epub 2010 Dec 21. Neuro Oncol. 2011. PMID: 21177338 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

70 results

Search Page

Filters